Search results
Results from the WOW.Com Content Network
The first oncolytic virus to be approved by a regulatory agency was a genetically modified adenovirus named H101 by Shanghai Sunway Biotech. It gained regulatory approval in 2005 from China's State Food and Drug Administration (SFDA) for the treatment of head and neck cancer. [17]
The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.
Nadofaragene firadenovec (Adstiladrin): treatment for bladder cancer [13] Obecabtagene autoleucel (Aucatzyl): treatment of acute lymphoblastic leukemia [14] [15] Onasemnogene abeparvovec (Zolgensma): AAV-based treatment for spinal muscular atrophy [16] Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID)
The FDA's accelerated approval to Tecelra was based on data from a 44-patient study, in which 43.2% of the participants showed partial or complete response to the treatment for an average duration ...
The US Food and Drug Administration has launched an investigation into certain treatments for cancer and whether these therapies themselves may be associated with the risk of developing secondary ...
A genetically modified organism (GMO) is any organism whose genetic material has been altered using genetic engineering techniques.The exact definition of a genetically modified organism and what constitutes genetic engineering varies, with the most common being an organism altered in a way that "does not occur naturally by mating and/or natural recombination". [1]
Genetically modified organisms refers to any plant, animal or microorganism that has been genetically altered, due to modern biotechnology like genetic engineering. Often, GMOs are labeled “GE ...
Cancer gene therapy was introduced in 1992/93 (Trojan et al. 1993). [167] The treatment of glioblastoma multiforme, the malignant brain tumor whose outcome is always fatal, was done using a vector expressing antisense IGF-I RNA (clinical trial approved by NIH protocol no.1602 24 November 1993, [168] and by the FDA in 1994). This therapy also ...